Developer docs
API playgroundTry for free, no card

Search company profiles

Candioli Pharma

Full company profile

uuid000yje3

Namestring
Candioli Pharma
Legal namestring
Candioli srl
Websiteurl
candioli.it
Company typeenum
Private
Founded yearint
1882
Descriptiontext

Candioli Pharma is an Italian pharmaceutical company founded in 1882 in Rome by Dr. Attilio Candioli and now headquartered in Beinasco (Turin), Italy. The company manufactures and sells a diversified portfolio of veterinary medicines and supplements, medical-surgical devices (insecticides and repellents), animal hygiene products, and human antiparasitic products, structured across four operating lines: Veterinary Line (Italian market), Human Line centered on the historic MOM brand, Candioli in the World (international distribution), and Vetark (exotic animals, acquired 2018). Core product families include the Florentero intestinal health line (FAST, ACT, Complex), BURAN respiratory formula, MOM antiparasitic products, and specific veterinary medicines (Milprazon, Marfloxin, Selames, Gastazole, Cystocure, OSTEOPEN, OTOXOLAN). The proprietary technology is built around a 4,226 m2 GMP-compliant production facility operated by wholly-owned subsidiary ACEL pharma Srl, with approximately 2,000 m2 of recently refurbished manufacturing space, ISO 9001:2023 quality certification, and Italian Ministry of Health authorization for veterinary medicines and medical-surgical devices.

The company's business model is built on a direct field sales force (scientific information representatives) visiting over 7,000 veterinary clinics daily across Italy, organized into two specialized teams with distinct therapeutic competencies. Domestic distribution is supplemented through pet shops, veterinary pharmacies, and human pharmacies for MOM products. International markets are served through export managers, distributors, and commercial partners in over 50 countries, with wholly-owned subsidiaries including ACEL pharma (production) and Vetark Products Ltd (UK). The company additionally offers third-party contract manufacturing services covering formulation development, production, packaging, and regulatory support. Customer engagement is reinforced through the Vetcampus digital training portal (launched July 2020), which provides training paths, webinars, case studies, and a VetCommunity. Revenue is generated primarily through one-time product sales across veterinary and human pharmaceutical categories, with no public pricing disclosure or subscription model evident.

The company is privately held under four generations of family ownership, with no external institutional investors or parent company identified. Leadership is composed of Luca Cravero Candioli (General Manager) and Dr. Enrica Candioli (President). The company has earned three consecutive Deloitte Best Managed Companies Awards (2020, 2021, 2023), Gender Equality Certification (2025), and registration in Italy's National Register of Historic Enterprises (2026).

Short descriptiontext

Candioli Pharma is an Italian family-owned pharmaceutical company founded in 1882 that manufactures and sells veterinary medicines, supplements, hygiene products, and antiparasitic treatments for animals, plus the historic MOM human antiparasitic brand, distributed through a direct field sales force covering 7,000+ Italian veterinary clinics and partners in 50+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeinasco, Italy
HQ citystring
Beinasco
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary pharmaceuticals, antiparasitic medicines, animal hygiene products, veterinary supplements, pet healthcare products
Industry3 codes
1Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm)
CodeHLAMAEADPrimaryYes
2Immune Support Supplements
CodeHLAMALAEPrimaryNo
3Veterinary Pharmaceutical Wholesalers & Distributors
CodeHLAMAIAAPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Veterinary Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model6 records
1Veterinary pharmaceutical products
TypeOne Time License
Description

Manufacture and sale of antiparasitic veterinary medicines for pets, birds, and athlete horses, including products for dogs, cats, horses, and exotic animals through brands including Florentero, Milprazon, Marfloxin, Selames, Gastazole, Cystocure, Evexia plus, OSTEOPEN, and OTOXOLAN.

candioli.it
2Human antiparasitic products (MOM line)
TypeOne Time License
Description

Production and commercialization of antiparasitic products for human use, including the historic MOM brand (shampoo, lotions, emulsions) for pediculosis treatment and prevention.

candioli.it
3Medical-surgical devices
TypeOne Time License
Description

Production and sale of insecticides for domestic and civil use and insect repellents for humans and animals in various forms (liquids, solutions, suspensions, sprays, shampoos, foams, powders, semisolids).

candioli.it
4Animal hygiene products
TypeOne Time License
Description

Production of dermo-protective lotions, lenitive shampoos, oral hygiene pastes, mouth rinses, ear hygiene products, and ointments for dogs, cats, birds, and horses.

candioli.it
5Third-party manufacturing (contract manufacturing)
TypeProfessional Services
Description

Candioli guarantees a complete service for the design, production and marketing of products for animals and humans on behalf of third parties, from raw material research to product analysis, formulation development, production, packaging, and technical-regulatory assistance.

candioli.it
6International export
TypeOne Time License
Description

Export of veterinary and human pharmaceutical products to over 50 countries through distributors and commercial agreements, including the UK subsidiary Vetark Products Ltd for exotic animal products.

candioli.it
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 16 records shown
1MOM
Description

Anti-lice range for human use; recognized as a historic brand (Marchio storico) for over 100 years

candioli.it
+15 more records
Core offering1 text field

Candioli Pharma manufactures and sells antiparasitic medicines for human use and a broad portfolio of veterinary products (medicines with antiparasitic action, medical-surgical devices such as insecticides and repellents, and animal hygiene products) covering pets, birds, athlete horses, and exotic animals. The company also provides contract manufacturing services for third parties, encompassing raw material research, formulation, production, packaging, and technical-regulatory assistance under GMP and ISO 9001 standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 7,000 veterinary clinics visited daily across Italy
+3 more records
Product overview1 text field

Candioli Pharma operates as a diversified pharmaceutical company with four main product lines: Veterinary Line (antiparasitic products, dermo-protective and hygiene products for pets, birds, and horses in Italy), Human Line featuring the historic MOM brand (anti-lice treatments for over 100 years), international distribution through Candioli in the World (present in 50+ countries), and Vetark (acquired UK brand for exotic animal products). The portfolio includes specific veterinary medicines like Milprazon (dewormer), Marfloxin (antibiotic), and Selames (spot-on parasite treatment), gastrointestinal supplements (Florentero Complex/FAST, Gastazole), respiratory products (BURAN), and bone health products (OSTEOPEN). The company also operates Vetcampus, a digital training platform for veterinarians.

Product and service16 records
1Florentero Complex
CategoryVeterinary intestinal health supplement
Description

Veterinary intestinal health product for dogs and cats that stabilizes physiological digestion in cases of acute and chronic diarrhea, containing over 11 billion probiotics with three bacterial strains, available in tablet and paste formats.

2Florentero FAST
CategoryVeterinary intestinal health supplement
Description

Veterinary product for acute intestinal absorption disorders in dogs and cats, combining clinoptilolite, tannic acid, probiotic Lactobacillus acidophilus CECT 4529, FOS prebiotics, and the HECO electrolyte complex to restore hydrosaline balance.

3BURAN
CategoryVeterinary respiratory supplement
Description

Veterinary respiratory function supplement for animals combining an exclusive blend of plant extracts (Arthrospira platensis, fermented pineapple, ivy, Glycyrrhiza glabra, Allium sativum, Thymus vulgaris, Hedera helix) with Vitamins C and E.

4Milprazon
CategoryVeterinary antiparasitic medicine
Description

Veterinary deworming medicine combining Milbemycin oxime and Praziquantel, available in multiple dosage strengths (2.5mg/25mg, 4mg/10mg, 12.5mg/125mg, and 16mg/40mg tablets) for dogs and cats.

5Marfloxin
CategoryVeterinary antibiotic medicine
Description

Veterinary antibiotic containing Marbofloxacin, available in 5mg, 20mg, and 80mg formulations for the treatment of bacterial infections in animals.

6Selames
CategoryVeterinary antiparasitic medicine
Description

Topical spot-on solution containing Selamectin for external parasite treatment in cats and dogs, available in multiple strengths from 15mg to 240mg.

7OSTEOPEN
CategoryVeterinary joint and bone health supplement
Description

Veterinary product formulated to support bone health in animals.

8Gastazole
CategoryVeterinary gastrointestinal product
Description

Gastrointestinal product for veterinary use addressing digestive disorders in animals.

9OTOXOLAN
CategoryVeterinary ear care product
Description

Veterinary product formulated for ear care applications in animals.

10Evexia plus
CategoryVeterinary healthcare product
Description

Veterinary product in Candioli's portfolio, presented at Zoomark 2023 as part of the company's expanding therapeutic range.

11Cystocure (including Cystocure pasta)
CategoryVeterinary urinary health product
Description

Veterinary urinary health product line including a pasta format addition for the management of lower urinary tract conditions in companion animals.

12MOM antiparasitic range (MOM, MOM Care, MOM Zero)
CategoryHuman antiparasitic medicine
Description

Historic Italian brand of human antiparasitic products for prevention and treatment of pediculosis (head lice), available as shampoos, lotions, and emulsions across the MOM, MOM Care, and MOM Zero sub-lines. Recognized as a historic Italian trademark with over 100 years of continuous market presence.

13Vetark product range for exotic animals
CategoryVeterinary product for exotic animals
Description

Range of products specifically formulated for exotic animals, marketed through the wholly-owned UK subsidiary Vetark Products Ltd acquired in 2018 as Candioli's first foreign subsidiary.

14Animal hygiene product range
CategoryAnimal hygiene product
Description

Range of animal hygiene products including dermo-protective lotions, lenitive shampoos, oral hygiene pastes, mouth rinses, ear hygiene products, and ointments for dogs, cats, birds, and horses, manufactured under UNI EN ISO 9001 quality standards.

15Medical-surgical devices (insecticides and repellents)
CategoryMedical-surgical device
Description

Insecticides for domestic and civil use and insect repellents for humans and animals, produced under authorization from the Italian Ministry of Health in various formats (liquids, solutions, suspensions, sprays, shampoos, foams, powders, semisolids).

16Contract manufacturing services for third parties
CategoryContract manufacturing services
Description

End-to-end contract manufacturing service covering raw material research, formulation development, production, packaging, product analysis, and technical-regulatory assistance for animal and human products on behalf of third-party clients, conducted under GMP rules at the ACEL pharma facility.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-01
Description

Local distributor in Brazil for WSAVA 2025 in Rio de Janeiro. Demonstrated professional passion and commitment in representing Candioli Pharma at the international veterinary congress.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-01-01
Description

Partnership with 21 associations and supply chain consortia for environmental labeling events. CONAI selected the Florentero ACT packaging as a Good Ideas product in the pharmaceutical sector for its innovative environmental labeling developed internally by Candioli.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Acquired in 2018 as Candioli Pharma's first foreign subsidiary, based in the UK. Specializes in products for exotic animals, expanding the company's international presence and product portfolio in the exotic pet segment.

4ExtonVet
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2004-01-01
Description

Acquired in 2004 as part of the company's international expansion strategy, contributing to the global growth of Candioli Pharma's veterinary product distribution.

candioli.it
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Production company of the Candioli group, authorized by the Italian Ministry of Health for production of veterinary medicines with antiparasitic action, medical-surgical devices (insecticides/repellents), and animal hygiene products. Operates the main production facility at Via Manzoni, 2, Beinasco (TO).

6International commercial partners (Europe, North America, South America, Asia)
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Candioli Pharma has commercial agreements with partners in European, North American, South American, and Asian countries. Products are distributed in over 50 countries through these partnerships.

candioli.it
Strategic tierMinorTypeOthers
Description

Candioli participated in Deloitte's Best Managed Companies multi-year growth program, receiving the BMC Award for three consecutive years (2020, 2021, 2023). The program provides expert guidance on business development and strengthening.

8ALTIS Graduate School of Sustainable Management, Università Cattolica del Sacro Cuore
Strategic tierMinorTypeOthers
Description

Academic partner in the Deloitte Best Managed Companies Award program. Contributes to the evaluation criteria for the award alongside ELITE-Gruppo Euronext and Piccola Industria di Confindustria.

candioli.it
9ELITE-Gruppo Euronext
Strategic tierMinorTypeOthers
Description

Partner in the Deloitte Best Managed Companies Award program supporting Italian business excellence alongside Confindustria and Altis.

candioli.it
Strategic tierMinorTypeOthers
Description

Confindustria's Piccola Industria is a partner in the Deloitte Best Managed Companies Award program recognizing excellence in Italian entrepreneurship.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Independent French veterinary pharmaceutical company focused on companion animals and livestock, with overlapping therapeutic areas (parasiticides, antibiotics, dermatology) and a European-centric manufacturing footprint similar to Candioli's.

TypeDirect peer
Description

France-based global animal-health pharmaceutical company with a comparable portfolio across parasiticides, dermatology, antibiotics and specialty nutrition for companion animals, fish and livestock. Closely comparable in product mix (especially parasiticides and dermatology) and in veterinary-clinic channel focus.

TypeEmerging player
Description

European CDMO offering third-party veterinary pharmaceutical manufacturing services. Comparable to Candioli's contract manufacturing offering as a more focused, smaller-scale specialist alternative for animal-health brands seeking outsourced production.

TypeDirect peer
Description

Global veterinary pharmaceutical group with strong European presence and a comparable focus on companion-animal parasiticides, vaccines and specialty products. Comparable as a privately held multi-category animal-health player pursuing international expansion.

TypeBroad incumbent
Description

Global animal-health division of Merck offering parasiticides (Bravecto, etc.), vaccines and pharmaceuticals. Direct competitor in parasiticide categories but with substantially larger R&D and distribution capabilities.

TypeDirect peer
Description

UK-listed veterinary pharmaceuticals specialist concentrated in companion-animal therapeutics, dermatology, endocrine and parasiticides. Highly comparable specialty-portfolio overlap and European veterinary distribution model before its 2024 take-private.

TypeBroad incumbent
Description

Largest global animal-health company offering parasiticides, vaccines, dermatology, diagnostics and nutrition. Overlaps with Candioli across multiple categories (notably parasiticides and dermatology) but operates at vastly broader scale and global reach.

TypeDirect peer
Description

Italian veterinary pharmaceutical manufacturer producing parasiticides, antibiotics and specialty products for companion and farm animals. Most direct domestic competitor and counterpart in scale, channel (Italian vet clinics) and product mix.

TypeDirect peer
Description

Spanish veterinary pharmaceutical manufacturer within the Invesa group, producing parasiticides, anti-infectives and specialties for companion animals. Comparable regional European competitor with similar GMP manufacturing and export focus.

TypeBroad incumbent
Description

Major incumbent in veterinary pharmaceuticals and vaccines across companion and production animals. Competes broadly with Candioli in parasiticides and respiratory therapeutics, though at much larger scale and with a global direct-market model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Candioli Pharma

Veterinary Pharmaceuticalscandioli.it

Candioli Pharma is an Italian family-owned pharmaceutical company founded in 1882 that manufactures and sells veterinary medicines, supplements, hygiene products, and antiparasitic treatments for animals, plus the historic MOM human antiparasitic brand, distributed through a direct field sales force covering 7,000+ Italian veterinary clinics and partners in 50+ countries.

What Candioli Pharma does

Candioli Pharma is an Italian pharmaceutical company founded in 1882 in Rome by Dr. Attilio Candioli and now headquartered in Beinasco (Turin), Italy. The company manufactures and sells a diversified portfolio of veterinary medicines and supplements, medical-surgical devices (insecticides and repellents), animal hygiene products, and human antiparasitic products, structured across four operating lines: Veterinary Line (Italian market), Human Line centered on the historic MOM brand, Candioli in the World (international distribution), and Vetark (exotic animals, acquired 2018). Core product families include the Florentero intestinal health line (FAST, ACT, Complex), BURAN respiratory formula, MOM antiparasitic products, and specific veterinary medicines (Milprazon, Marfloxin, Selames, Gastazole, Cystocure, OSTEOPEN, OTOXOLAN). The proprietary technology is built around a 4,226 m2 GMP-compliant production facility operated by wholly-owned subsidiary ACEL pharma Srl, with approximately 2,000 m2 of recently refurbished manufacturing space, ISO 9001:2023 quality certification, and Italian Ministry of Health authorization for veterinary medicines and medical-surgical devices.

The company's business model is built on a direct field sales force (scientific information representatives) visiting over 7,000 veterinary clinics daily across Italy, organized into two specialized teams with distinct therapeutic competencies. Domestic distribution is supplemented through pet shops, veterinary pharmacies, and human pharmacies for MOM products. International markets are served through export managers, distributors, and commercial partners in over 50 countries, with wholly-owned subsidiaries including ACEL pharma (production) and Vetark Products Ltd (UK). The company additionally offers third-party contract manufacturing services covering formulation development, production, packaging, and regulatory support. Customer engagement is reinforced through the Vetcampus digital training portal (launched July 2020), which provides training paths, webinars, case studies, and a VetCommunity. Revenue is generated primarily through one-time product sales across veterinary and human pharmaceutical categories, with no public pricing disclosure or subscription model evident.

The company is privately held under four generations of family ownership, with no external institutional investors or parent company identified. Leadership is composed of Luca Cravero Candioli (General Manager) and Dr. Enrica Candioli (President). The company has earned three consecutive Deloitte Best Managed Companies Awards (2020, 2021, 2023), Gender Equality Certification (2025), and registration in Italy's National Register of Historic Enterprises (2026).

Candioli Pharma firmographics

Firmographics
Name
Candioli Pharma
Legal name
Candioli srl
Website
https://candioli.it
Company type
Private
Founded year
1882
Operating status
Operating
Headcount range
11–50 employees
Short description
Candioli Pharma is an Italian family-owned pharmaceutical company founded in 1882 that manufactures and sells veterinary medicines, supplements, hygiene products, and antiparasitic treatments for animals, plus the historic MOM human antiparasitic brand, distributed through a direct field sales force covering 7,000+ Italian veterinary clinics and partners in 50+ countries.
Ownership category
akta.pro rank

Candioli Pharma industry classification

Industry
Product category
Veterinary Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm) (HLAMAEAD)
akta.pro secondary industries
Immune Support Supplements (HLAMALAE), Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA)

Keywords

  • Veterinary pharmaceuticals
  • Antiparasitic medicines
  • Animal hygiene products
  • Veterinary supplements
  • Pet healthcare products

Where Candioli Pharma is headquartered

Location

Headquarters

HQ city
Beinasco
HQ country
Italy
HQ region
Europe

Offices3 records

Markets served

Candioli Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Veterinary pharmaceutical products: Manufacture and sale of antiparasitic veterinary medicines for pets, birds, and athlete horses, including products for dogs, cats, horses, and exotic animals through brands including Florentero, Milprazon, Marfloxin, Selames, Gastazole, Cystocure, Evexia plus, OSTEOPEN, and OTOXOLAN.
  2. Human antiparasitic products (MOM line): Production and commercialization of antiparasitic products for human use, including the historic MOM brand (shampoo, lotions, emulsions) for pediculosis treatment and prevention.
  3. Medical-surgical devices: Production and sale of insecticides for domestic and civil use and insect repellents for humans and animals in various forms (liquids, solutions, suspensions, sprays, shampoos, foams, powders, semisolids).
  4. Animal hygiene products: Production of dermo-protective lotions, lenitive shampoos, oral hygiene pastes, mouth rinses, ear hygiene products, and ointments for dogs, cats, birds, and horses.
  5. Third-party manufacturing (contract manufacturing): Candioli guarantees a complete service for the design, production and marketing of products for animals and humans on behalf of third parties, from raw material research to product analysis, formulation development, production, packaging, and technical-regulatory assistance.
  6. International export: Export of veterinary and human pharmaceutical products to over 50 countries through distributors and commercial agreements, including the UK subsidiary Vetark Products Ltd for exotic animal products.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Candioli Pharma product offering

Product offering

Core offering

Candioli Pharma manufactures and sells antiparasitic medicines for human use and a broad portfolio of veterinary products (medicines with antiparasitic action, medical-surgical devices such as insecticides and repellents, and animal hygiene products) covering pets, birds, athlete horses, and exotic animals. The company also provides contract manufacturing services for third parties, encompassing raw material research, formulation, production, packaging, and technical-regulatory assistance under GMP and ISO 9001 standards.

Product overview

Candioli Pharma operates as a diversified pharmaceutical company with four main product lines: Veterinary Line (antiparasitic products, dermo-protective and hygiene products for pets, birds, and horses in Italy), Human Line featuring the historic MOM brand (anti-lice treatments for over 100 years), international distribution through Candioli in the World (present in 50+ countries), and Vetark (acquired UK brand for exotic animal products). The portfolio includes specific veterinary medicines like Milprazon (dewormer), Marfloxin (antibiotic), and Selames (spot-on parasite treatment), gastrointestinal supplements (Florentero Complex/FAST, Gastazole), respiratory products (BURAN), and bone health products (OSTEOPEN). The company also operates Vetcampus, a digital training platform for veterinarians.

Differentiator

Problem solved

Functional benefit

Brands

  • MOM: Anti-lice range for human use; recognized as a historic brand (Marchio storico) for over 100 years
  • MOM Care
  • MOM Zero
  • Florentero
  • BURAN
  • Evexia plus
  • Cystocure
  • Gastrocure
  • Vetark
  • Vetcampus
  • Matosto
  • Marfloxin
  • Milprazon
  • Selames
  • Otoxolan
  • Osteopen

Products and services

  • Florentero Complex Veterinary intestinal health product for dogs and cats that stabilizes physiological digestion in cases of acute and chronic diarrhea, containing over 11 billion probiotics with three bacterial strains, available in tablet and paste formats.
  • Florentero FAST Veterinary product for acute intestinal absorption disorders in dogs and cats, combining clinoptilolite, tannic acid, probiotic Lactobacillus acidophilus CECT 4529, FOS prebiotics, and the HECO electrolyte complex to restore hydrosaline balance.
  • BURAN Veterinary respiratory function supplement for animals combining an exclusive blend of plant extracts (Arthrospira platensis, fermented pineapple, ivy, Glycyrrhiza glabra, Allium sativum, Thymus vulgaris, Hedera helix) with Vitamins C and E.
  • Milprazon Veterinary deworming medicine combining Milbemycin oxime and Praziquantel, available in multiple dosage strengths (2.5mg/25mg, 4mg/10mg, 12.5mg/125mg, and 16mg/40mg tablets) for dogs and cats.
  • Marfloxin Veterinary antibiotic containing Marbofloxacin, available in 5mg, 20mg, and 80mg formulations for the treatment of bacterial infections in animals.
  • Selames Topical spot-on solution containing Selamectin for external parasite treatment in cats and dogs, available in multiple strengths from 15mg to 240mg.
  • OSTEOPEN Veterinary product formulated to support bone health in animals.
  • Gastazole Gastrointestinal product for veterinary use addressing digestive disorders in animals.
  • OTOXOLAN Veterinary product formulated for ear care applications in animals.
  • Evexia plus Veterinary product in Candioli's portfolio, presented at Zoomark 2023 as part of the company's expanding therapeutic range.
  • Cystocure (including Cystocure pasta) Veterinary urinary health product line including a pasta format addition for the management of lower urinary tract conditions in companion animals.
  • MOM antiparasitic range (MOM, MOM Care, MOM Zero) Historic Italian brand of human antiparasitic products for prevention and treatment of pediculosis (head lice), available as shampoos, lotions, and emulsions across the MOM, MOM Care, and MOM Zero sub-lines. Recognized as a historic Italian trademark with over 100 years of continuous market presence.
  • Vetark product range for exotic animals Range of products specifically formulated for exotic animals, marketed through the wholly-owned UK subsidiary Vetark Products Ltd acquired in 2018 as Candioli's first foreign subsidiary.
  • Animal hygiene product range Range of animal hygiene products including dermo-protective lotions, lenitive shampoos, oral hygiene pastes, mouth rinses, ear hygiene products, and ointments for dogs, cats, birds, and horses, manufactured under UNI EN ISO 9001 quality standards.
  • Medical-surgical devices (insecticides and repellents) Insecticides for domestic and civil use and insect repellents for humans and animals, produced under authorization from the Italian Ministry of Health in various formats (liquids, solutions, suspensions, sprays, shampoos, foams, powders, semisolids).
  • Contract manufacturing services for third parties End-to-end contract manufacturing service covering raw material research, formulation development, production, packaging, product analysis, and technical-regulatory assistance for animal and human products on behalf of third-party clients, conducted under GMP rules at the ACEL pharma facility.

Quantifiable outcome

  • Over 7,000 veterinary clinics visited daily across Italy
  • +3 more outcomes

Companies that use Candioli Pharma

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Candioli Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Candioli Pharma partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered major, minor and core.

  • BioctalmajorChannel Partner/ Reseller/ Distributor · 1 January 2025Local distributor in Brazil for WSAVA 2025 in Rio de Janeiro. Demonstrated professional passion and commitment in representing Candioli Pharma at the international veterinary congress.
  • CONAI (Consorzio Nazionale Imballaggi)minorGTM or Marketing Partner · 1 January 2021Partnership with 21 associations and supply chain consortia for environmental labeling events. CONAI selected the Florentero ACT packaging as a Good Ideas product in the pharmaceutical sector for its innovative environmental labeling developed internally by Candioli.
  • Vetark Products LtdcoreStrategic or Co-development Partner · 1 January 2018Acquired in 2018 as Candioli Pharma's first foreign subsidiary, based in the UK. Specializes in products for exotic animals, expanding the company's international presence and product portfolio in the exotic pet segment.
  • ExtonVetcoreStrategic or Co-development Partner · 1 January 2004Acquired in 2004 as part of the company's international expansion strategy, contributing to the global growth of Candioli Pharma's veterinary product distribution.
  • ACEL pharma SrlcoreStrategic or Co-development PartnerProduction company of the Candioli group, authorized by the Italian Ministry of Health for production of veterinary medicines with antiparasitic action, medical-surgical devices (insecticides/repellents), and animal hygiene products. Operates the main production facility at Via Manzoni, 2, Beinasco (TO).
  • International commercial partners (Europe, North America, South America, Asia)majorChannel Partner/ Reseller/ DistributorCandioli Pharma has commercial agreements with partners in European, North American, South American, and Asian countries. Products are distributed in over 50 countries through these partnerships.
  • Deloitte PrivateminorOthersCandioli participated in Deloitte's Best Managed Companies multi-year growth program, receiving the BMC Award for three consecutive years (2020, 2021, 2023). The program provides expert guidance on business development and strengthening.
  • ALTIS Graduate School of Sustainable Management, Università Cattolica del Sacro CuoreminorOthersAcademic partner in the Deloitte Best Managed Companies Award program. Contributes to the evaluation criteria for the award alongside ELITE-Gruppo Euronext and Piccola Industria di Confindustria.
  • ELITE-Gruppo EuronextminorOthersPartner in the Deloitte Best Managed Companies Award program supporting Italian business excellence alongside Confindustria and Altis.
  • Confindustria (Piccola Industria)minorOthersConfindustria's Piccola Industria is a partner in the Deloitte Best Managed Companies Award program recognizing excellence in Italian entrepreneurship.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Candioli Pharma competitors and assessment

Company assessment

Direct peers

  • Vetoquinol: Independent French veterinary pharmaceutical company focused on companion animals and livestock, with overlapping therapeutic areas (parasiticides, antibiotics, dermatology) and a European-centric manufacturing footprint similar to Candioli's.
  • Virbac: France-based global animal-health pharmaceutical company with a comparable portfolio across parasiticides, dermatology, antibiotics and specialty nutrition for companion animals, fish and livestock. Closely comparable in product mix (especially parasiticides and dermatology) and in veterinary-clinic channel focus.
  • Ceva Santé Animale: Global veterinary pharmaceutical group with strong European presence and a comparable focus on companion-animal parasiticides, vaccines and specialty products. Comparable as a privately held multi-category animal-health player pursuing international expansion.
  • Dechra Pharmaceuticals: UK-listed veterinary pharmaceuticals specialist concentrated in companion-animal therapeutics, dermatology, endocrine and parasiticides. Highly comparable specialty-portfolio overlap and European veterinary distribution model before its 2024 take-private.
  • Fatro: Italian veterinary pharmaceutical manufacturer producing parasiticides, antibiotics and specialty products for companion and farm animals. Most direct domestic competitor and counterpart in scale, channel (Italian vet clinics) and product mix.
  • Calier (Invesa group): Spanish veterinary pharmaceutical manufacturer within the Invesa group, producing parasiticides, anti-infectives and specialties for companion animals. Comparable regional European competitor with similar GMP manufacturing and export focus.

Emerging players

  • ACM Pharma (animal health CDMO): European CDMO offering third-party veterinary pharmaceutical manufacturing services. Comparable to Candioli's contract manufacturing offering as a more focused, smaller-scale specialist alternative for animal-health brands seeking outsourced production.

Broad incumbents

  • MSD Animal Health (Merck Animal Health): Global animal-health division of Merck offering parasiticides (Bravecto, etc.), vaccines and pharmaceuticals. Direct competitor in parasiticide categories but with substantially larger R&D and distribution capabilities.
  • Zoetis: Largest global animal-health company offering parasiticides, vaccines, dermatology, diagnostics and nutrition. Overlaps with Candioli across multiple categories (notably parasiticides and dermatology) but operates at vastly broader scale and global reach.
  • Boehringer Ingelheim Animal Health: Major incumbent in veterinary pharmaceuticals and vaccines across companion and production animals. Competes broadly with Candioli in parasiticides and respiratory therapeutics, though at much larger scale and with a global direct-market model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Candioli Pharma social profiles

Digital presence

Candioli Pharma compliance and trust

Trust signal

Compliance2 records

Candioli Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Candioli Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Candioli Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Candioli Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Candioli Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Candioli Pharma

What does Candioli Pharma do?

Candioli Pharma manufactures and sells antiparasitic medicines for human use and a broad portfolio of veterinary products (medicines with antiparasitic action, medical-surgical devices such as insecticides and repellents, and animal hygiene products) covering pets, birds, athlete horses, and exotic animals. The company also provides contract manufacturing services for third parties, encompassing raw material research, formulation, production, packaging, and technical-regulatory assistance under GMP and ISO 9001 standards.

Is Candioli Pharma a public or private company?

Candioli Pharma is a private company. It is classified as family owned and is currently operating.

When was Candioli Pharma founded?

Candioli Pharma was founded in 1882. It employs 11 to 50 people.

Where is Candioli Pharma based?

Candioli Pharma is headquartered in Beinasco, Italy, in the Europe region.

How does Candioli Pharma make money?

Six revenue lines are on record. Veterinary pharmaceutical products are the primary driver. The others are human antiparasitic products (MOM line), medical-surgical devices, animal hygiene products, third-party manufacturing (contract manufacturing) and international export.

Who are Candioli Pharma's main competitors?

Direct peers on record are Vetoquinol, Virbac, Ceva Santé Animale, Dechra Pharmaceuticals, Fatro and Calier (Invesa group). ACM Pharma (animal health CDMO) is listed as an emerging player. Broad incumbents are MSD Animal Health (Merck Animal Health), Zoetis and Boehringer Ingelheim Animal Health.

Does Candioli Pharma have an API?

No public API is recorded for Candioli Pharma.

What industry is Candioli Pharma in?

Candioli Pharma's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAD, Parasiticides & Ectoparasite Control (Flea/Tick/Heartworm), with a secondary code of HLAMALAE, Immune Support Supplements. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales